BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31506280)

  • 1. Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion.
    Zarei M; Du H; Nassar AH; Yan RE; Giannikou K; Johnson SH; Lam HC; Henske EP; Wang Y; Zhang T; Asara J; Kwiatkowski DJ
    J Exp Med; 2019 Nov; 216(11):2635-2652. PubMed ID: 31506280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
    Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
    IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
    Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ
    PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent.
    Parkhitko A; Myachina F; Morrison TA; Hindi KM; Auricchio N; Karbowniczek M; Wu JJ; Finkel T; Kwiatkowski DJ; Yu JJ; Henske EP
    Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12455-60. PubMed ID: 21746920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
    Li H; Jin F; Jiang K; Ji S; Wang L; Ni Z; Chen X; Hu Z; Zhang H; Liu Y; Qin Y; Zha X
    Oncotarget; 2016 May; 7(19):28435-47. PubMed ID: 27078846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations.
    Aksoylu IS; Martin P; Robert F; Szkop KJ; Redmond NE; Bhattacharyya S; Wang J; Chen S; Beauchamp RL; Nobeli I; Pelletier J; Larsson O; Ramesh V
    Mol Autism; 2023 Oct; 14(1):39. PubMed ID: 37880800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
    Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H
    Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
    Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway.
    Chow PM; Chang YW; Kuo KL; Lin WC; Liu SH; Huang KH
    Cancer Lett; 2021 Jun; 507():70-79. PubMed ID: 33741425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer.
    Yang Y; Jiang D; Zhou Z; Xiong H; Yang X; Peng G; Xia W; Wang S; Lei H; Zhao J; Qian Z; Wu S; Pang J
    Cell Oncol (Dordr); 2021 Aug; 44(4):871-887. PubMed ID: 33905040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Farnesyltransferase Inhibitor Restores Cognitive Deficits in
    Sugiura H; Shimada T; Moriya-Ito K; Goto JI; Fujiwara H; Ishii R; Shitara H; Taya C; Fujii S; Kobayashi T; Hino O; Worley PF; Yamagata K
    J Neurosci; 2022 Mar; 42(12):2598-2612. PubMed ID: 35121635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
    Sun B; Mason S; Wilson RC; Hazard SE; Wang Y; Fang R; Wang Q; Yeh ES; Yang M; Roberts TM; Zhao JJ; Wang Q
    Oncogene; 2020 Jan; 39(1):50-63. PubMed ID: 31462705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
    Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
    J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Characterization of a Subependymal Giant Astrocytoma-Like Cell Line from Murine Astrocyte with mTORC1 Hyperactivation.
    Tang X; Angst G; Haas M; Yang F; Wang C
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
    Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
    J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of acid ceramidase contributes to tumor progression in tuberous sclerosis complex.
    Astrinidis A; Li C; Zhang EY; Zhao X; Zhao S; Guo M; Olatoke T; Mattam U; Huang R; Zhang AG; Pitstick L; Kopras EJ; Gupta N; Jandarov R; Smith EP; Fugate E; Lindquist D; Markiewski MM; Karbowniczek M; Wikenheiser-Brokamp KA; Setchell KDR; McCormack FX; Xu Y; Yu JJ
    JCI Insight; 2023 May; 8(9):. PubMed ID: 36927688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal glycogen storage in tuberous sclerosis complex caused by impairment of mTORC1-dependent and -independent signaling pathways.
    Pal R; Xiong Y; Sardiello M
    Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2977-2986. PubMed ID: 30728291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.
    Medvetz D; Sun Y; Li C; Khabibullin D; Balan M; Parkhitko A; Priolo C; Asara JM; Pal S; Yu J; Henske EP
    Mol Cancer Res; 2015 Jan; 13(1):50-62. PubMed ID: 25185584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1.
    Di Nardo A; Wertz MH; Kwiatkowski E; Tsai PT; Leech JD; Greene-Colozzi E; Goto J; Dilsiz P; Talos DM; Clish CB; Kwiatkowski DJ; Sahin M
    Hum Mol Genet; 2014 Jul; 23(14):3865-74. PubMed ID: 24599401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.